Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 165 results found since Jan 2013.
The Berkowitz Law Firm LLC Announces that it is Evaluating Potential...
As the FDA investigates the potential risk of stroke, heart attack and death among men who use testosterone replacement therapy, the Connecticut defective drug lawyers of The Berkowitz Law Firm LLC...(PRWeb May 20, 2014)Read the full story at http://www.prweb.com/releases/testosterone-heart-risk/berkowitz-law-firm/prweb11849309.htm
Source: PRWeb: Medical Pharmaceuticals - May 20, 2014 Category: Pharmaceuticals Source Type: news
Merck's Zontivity gets FDA approval to reduce heart attacks and stroke risk in patients
Merck has received approval from the US Food and Drug Administration (FDA) for Zontivity (vorapaxar) for people at high-risk of heart attack or stroke.
Source: Pharmaceutical Technology - May 13, 2014 Category: Pharmaceuticals Source Type: news
FDA Approves Novel Merck Drug To Prevent Heart Attacks And Strokes
The FDA today approved vorapaxar (Zontivity), Merck's once-troubled platelet receptor antagonist, to reduce the risk of myocardial infarction (heart attack), stroke, cardiovascular death, and revascularization procedures. The drug is approved for use in people with a history of MI or peripheral arterial disease. The approval represents an amazing turnaround for a drug that had experienced nearly as many ups and downs as an amusement park roller coaster.
Source: Forbes.com Healthcare News - May 8, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
FDA Comes Out Against Aspirin To Prevent First Heart Attacks
In the latest development in a long-simmering debate, the FDA has announced that aspirin should not be marketed for the prevention of a first heart attack or stroke in people with no history of cardiovascular disease. The announcement follows FDA's rejection on Friday of Bayer Healthcare's decade-old petition requesting approval of a primary prevention indication.
Source: Forbes.com Healthcare News - May 5, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Safety Announcement Issued by FDA to Investigate Risk of Stroke, Heart...
Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, reports that the FDA has issued a Safety Announcement that it will investigate the risk of stroke, heart attack, and death for men...(PRWeb March 16, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11673176.htm
Source: PRWeb: Medical Pharmaceuticals - March 16, 2014 Category: Pharmaceuticals Source Type: news
Boston Heart Enables Healthcare Providers to Better Identify Near-Term Risk of Heart Attack or Stroke with Launch of an Important Inflammation Marker, Myeloperoxidase (MPO)
A significant addition that complements the company's innovative suite of diagnostics and services, Boston Heart's MPO is easy for clinicians to use and FDA-cleared.
FRAMINGHAM, Mass., March 6, 2014 -- (Healthcare Sales & Marketing Network) -- Boston H... Diagnostics, Cardiology, Product LaunchBoston Heart Diagnostics, myeloperoxidase, MPO test, heart attack
Source: HSMN NewsFeed - March 6, 2014 Category: Pharmaceuticals Source Type: news
The Onder Law Firm Announces Launch of National AndroGel Testosterone...
National pharmaceutical and product safety law firm offers confidential case review to men who suffered from heart attack or stroke while taking AndroGel or a similar testosterone product.(PRWeb February 25, 2014)Read the full story at http://www.prweb.com/releases/androgel-testosterone/heart-attack-lawsuit/prweb11613646.htm
Source: PRWeb: Medical Pharmaceuticals - February 25, 2014 Category: Pharmaceuticals Source Type: news
Testosterone Replacement Therapy found to be linked to Heart Problems
The Long Island law firm of Rudolph F. X. Migliore, P. C. provides legal advice to those that been treated for low testosterone and suffered a heart attack, stroke, pulmonary embolism or cardiac...(PRWeb February 25, 2014)Read the full story at http://www.prweb.com/releases/2014/02/prweb11606413.htm
Source: PRWeb: Medical Pharmaceuticals - February 25, 2014 Category: Pharmaceuticals Source Type: news
Every 34 seconds someone has a heart attack in the United States. How can we work together to improve prevention and treatment of cardiovascular disease to save lives?
conversationsphrmapediaphrma conversationsOpinion1201Heart disease is a major concern for all Americans, but no group is more significantly affected by it than the African American community.
African Americans are less likely to have their cardiovascular disease treated according to evidence-based guidelines, and when it comes to surgery, African Americans are three times more likely to be operated on by a high-risk surgeon.
Unsurprisingly, this divide in care is leads to a divide in health outcomes. The statistics are eye-opening: African American men and women are 76 and 54 percent more likely than their white counte...
Source: PHRMA - February 7, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
FDA Probes Risks of Testosterone-Boosting Drugs
The FDA said it is investigating the possible increased risk of stroke, heart attack and death in men who are taking testosterone-boosting products for the condition widely called "low-T."
Source: WSJ.com: Health - January 31, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today said it was
pleased with the U.S. Food and Drug Administration (FDA)’s
Cardiovascular and Renal Drugs Advisory Committee’s recommendation for
approval of vorapaxar. Vorapaxar is the company’s investigational
antiplatelet medicine for the reduction of atherothrombotic events, when
added to standard of care, in patients with a history of heart attack
and no history of stroke or transient ischemic attack.
...
Source: Merck.com - Research and Development News - January 15, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for...
The Firm is actively filing claims on behalf of individuals who allegedly suffered a stroke, heart attack, sudden cardiac death, or another heart-related injury after undergoing a dialysis treatment...(PRWeb December 08, 2013)Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11377005.htm
Source: PRWeb: Medical Pharmaceuticals - December 9, 2013 Category: Pharmaceuticals Source Type: news
Testosterone Therapy Tied to Heart Risks
Testosterone therapy raised the risk of death, heart attack and stroke by about 30% in a group of veterans with a history of heart disease, according to a new study.
Source: WSJ.com: Health - November 6, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
New GranuFlo Lawsuit Website from Bernstein Liebhard LLP Provides...
The Firm is eager to hear from any dialysis patient who may have suffered a stroke, heart attack, sudden cardiac death or another cardiovascular injury following treatment with Granuflo.(PRWeb October 27, 2013)Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11271730.htm
Source: PRWeb: Medical Pharmaceuticals - October 27, 2013 Category: Pharmaceuticals Source Type: news
